Last reviewed · How we verify
Olaparib Treatment B
Olaparib (AstraZeneca) is a first-in-class poly(ADP-ribose) polymerase (PARP) inhibitor small molecule that traps PARP on DNA lesions, preventing repair of single-strand breaks and inducing synthetic lethality in BRCA-mutated and homologous recombination-deficient tumors. Currently in Phase 1 development as 'Treatment B,' the compound is being evaluated across multiple cancer indications including ovarian cancer, bladder cancer, pancreatic cancer, and adrenal tumors in combination with chemotherapy, immunotherapy, and other targeted agents. Olaparib has achieved MHRA licensure and is established as a standard-of-care PARP inhibitor with peak sales exceeding $1.5B annually, competing against rucaparib and niraparib in the PARP inhibitor class. The Phase 1 program focuses on bioavailability optimization, combination strategies with ATR inhibitors and immunotherapies, and expansion into additional solid tumor types with specific biomarker enrichment. Commercial significance is substantial given the large addressable market in platinum-sensitive ovarian cancer, BRCA-mutated breast cancer, and emerging indications in pancreatic and endometrial cancers.
At a glance
| Generic name | Olaparib Treatment B |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Nausea
- Dermatitis
- Mucositis
- Vomiting
- Anaemia
- Anemia
- Dyspnoea
- Weight Loss
- Xerostomia
- Neutrophil count decreased
- Acneform rash
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olaparib Treatment B CI brief — competitive landscape report
- Olaparib Treatment B updates RSS · CI watch RSS
- AstraZeneca portfolio CI